Investigational drug · Phase 3
HL-1186
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Postoperative Pain, Moderate to Severe Acute Postoperative Pain, Postherpetic Neuralgia ( PHN ).
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
7
Any phase or sponsor naming "HL-1186"
First trial start
2025
Aug 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HL-1186", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postoperative Pain
- Moderate to Severe Acute Postoperative Pain
- Postherpetic Neuralgia ( PHN )
- Diabetic Peripheral Neuropathic Pain
Approved drugs for the same conditions: Neuropathic pain · Cardiovascular and metabolic · Neurology · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "HL-1186" as an intervention, largest first.
- Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal SurgeryPivotal-lookingRecruiting
Shanghai Huilun Pharmaceutical Co., Ltd.Industry
NCT07709598 · 330 participants (planned) · Start May 11, 2026 · Primary completion Oct 2026
Drug: HL-1186; HL-1186 placebo and 2 more · For: Postoperative Pain
Sites: Chengdu, China
- Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic SurgeryPivotal-lookingRecruiting
Shanghai Huilun Pharmaceutical Co., Ltd.Industry
NCT07699601 · 330 participants (planned) · Start May 9, 2026 · Primary completion Oct 2026
Drug: HL-1186; HL-1186 placebo and 2 more · For: Postoperative Pain
Sites: Changsha, China
- A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic NeuralgiaPivotal-lookingRecruiting
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
NCT07758920 · 200 participants (planned) · Start Aug 2026 · Primary completion Jun 2027
Drug: HL-1186; HL-1186 placebo and 2 more · For: Postherpetic Neuralgia ( PHN )
Sites: Beijing, China
- Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic PainPivotal-lookingNot yet recruiting
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
NCT07159243 · 180 participants (planned) · Start Sep 2025 · Primary completion Oct 2026
Drug: HL-1186; HL-1186 and 1 more · For: Diabetic Peripheral Neuropathic Pain
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
NCT06912295 · 76 participants (planned) · Start Mar 21, 2025 · Primary completion Aug 30, 2025
Drug: HL-1186; HL-1186 placebo · For: Healthy Participants
Sites: Wuxi, China
- Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After SurgeryRecruiting
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
NCT07147049 · 72 participants (planned) · Start Aug 8, 2025 · Primary completion Dec 2025
Drug: HL-1186; HL-1186 placebo · For: Moderate to Severe Acute Postoperative Pain
Sites: Chengdu, China
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
NCT07311369 · 40 participants (planned) · Start Dec 2025 · Primary completion Feb 2026
Drug: HL-1186; HL-1186 placebo · For: Moderate to Severe Acute Postoperative Pain
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Postoperative Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.